Vaxcyte, Inc. (PCVX)
NASDAQ: PCVX · Real-Time Price · USD
78.14
-3.03 (-3.73%)
At close: Jan 14, 2025, 4:00 PM
78.10
-0.04 (-0.05%)
After-hours: Jan 14, 2025, 5:01 PM EST
Vaxcyte Employees
Vaxcyte had 254 employees as of December 31, 2023. The number of employees increased by 96 or 60.76% compared to the previous year.
Employees
254
Change (1Y)
96
Growth (1Y)
60.76%
Revenue / Employee
n/a
Profits / Employee
-$1,998,614
Market Cap
9.74B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 254 | 96 | 60.76% |
Dec 31, 2022 | 158 | 69 | 77.53% |
Dec 31, 2021 | 89 | 31 | 53.45% |
Dec 31, 2020 | 58 | 15 | 34.88% |
Dec 31, 2019 | 43 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
PCVX News
- 31 minutes ago - Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy - Seeking Alpha
- 8 days ago - Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm - PRNewsWire
- 6 weeks ago - Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants - GlobeNewsWire
- 2 months ago - Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs - GlobeNewsWire
- 2 months ago - Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference - GlobeNewsWire
- 4 months ago - Vaxcyte's Broad-Spectrum Pneumococcal Vaccines Poised For Market Dominance By 2027 - Seeking Alpha
- 4 months ago - Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire